Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Equities
TEVA
IL0006290147
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,073 ILa | -0.21% | -1.59% | +59.19% |
Sales 2024 * | 15.95B 5,872B | Sales 2025 * | 16.52B 6,084B | Capitalization | 18.8B 6,924B |
---|---|---|---|---|---|
Net income 2024 * | 820M 302B | Net income 2025 * | 1.39B 511B | EV / Sales 2024 * | 2.12 x |
Net Debt 2024 * | 14.93B 5,496B | Net Debt 2025 * | 12.41B 4,569B | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
12.4
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.44% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 day | -0.21% | ||
1 week | -1.59% | ||
Current month | +15.19% | ||
1 month | +23.11% | ||
3 months | +23.99% | ||
6 months | +64.00% | ||
Current year | +59.19% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 59 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 6,073 | -0.21% | 1,258,396 |
24-05-27 | 6,086 | -0.26% | 174,639 |
24-05-26 | 6,102 | -1.34% | 335,935 |
24-05-23 | 6,185 | -0.80% | 1,003,446 |
24-05-22 | 6,235 | +2.55% | 1,656,060 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 28, 2024 at 10:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B |
- Stock Market
- Equities
- TEVA Stock
- TEVA Stock